<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00949351</url>
  </required_header>
  <id_info>
    <org_study_id>Lerdsin 36/52</org_study_id>
    <nct_id>NCT00949351</nct_id>
  </id_info>
  <brief_title>Safety of Add on Aliskiren to Angiotensin Converting Enzyme Inhibitor (ACEI) and Angiotensin I Receptor Blocker (ARB) Treatment in Type 2 Diabetes With Nephropathy</brief_title>
  <official_title>Safety of Add on Aliskiren to ACEI and ARB Treatment in Type 2 Diabetes With Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lerdsin General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lerdsin General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Activation of renin-angiotensin plays a crucial role diabetic nephropathy. Angiotensin
      converting enzyme inhibitor (ACEI) and Angiotensin I receptor blocker (ARB) has been shown
      renoprotection whether it was used alone or in combination. Aliskiren is a direct renin
      inhibitor (DRI) that has shown renal benefits and safety when combined with ARB. However, to
      date, the safety of add on aliskiren to the combination treatment of ACEI and ARB in diabetic
      nephropathy patients remains to elucidate.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">September 2010</completion_date>
  <primary_completion_date type="Anticipated">July 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess short-term safety of the combination of aliskiren 300 mg/valsartan 160 mg /enalapril 20 mg in patients with diabetic nephropathy</measure>
    <time_frame>12 wk after randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of systolic blood pressure</measure>
    <time_frame>12 wk after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of proteinuria</measure>
    <time_frame>12 wk after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in GFR/mo</measure>
    <time_frame>12 wk after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Serum prorenin level compare to baseline</measure>
    <time_frame>12 wk after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Urinary TGFb1 compare to baseline</measure>
    <time_frame>12 wk after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Type 2 Diabetes With Nephropathy</condition>
  <arm_group>
    <arm_group_label>Aliskiren</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren 300mg/d</intervention_name>
    <description>Aliskiren 300mg/d v.s. placebo for 12wk</description>
    <arm_group_label>Aliskiren</arm_group_label>
    <other_name>Rasilez (Thailand)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type2 diabetes patients

          -  Age &lt;30yrs-70yrs&gt;

          -  Overt proteinuria (Urinary protein creatinine ratio &gt; 200mg/g 2 times or more during
             past 6 Mo)

          -  Scr &lt; 2.5 mg/dL

          -  HbA1C &lt; 7.5

          -  Systolic blood pressure &gt; 160 mmHg without antihypertensive drugs or &gt; 140 with
             antihypertensive drug

          -  No history of previous cardiovascular event (Stroke, Myocardial infarction, unstable
             angina, hospitalization, surgical correction PVD or PVD with claudication)

          -  No hospitalization within 1 yr except for elective surgery

        Exclusion Criteria:

          -  Physical examination found or suspected serious co-morbid (AF, carotid bruit,
             structural heart disease, cirrhosis and decompensate liver disease)

          -  Non adherence to protocol

          -  Intolerable to ACEI or ARB during run-in

          -  Abnormal liver function test at the run-in period

          -  Rapid declining renal function (SCr increase &gt; 40%) during run-in

          -  Hyperkalemia (serum K &gt; 5.5 mEq/L at randomization)

          -  Malignancy detected o

          -  SBP lower than 110 mmHg (at randomization)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Krissanapong Manotham, Dr</last_name>
    <phone>662 3539799</phone>
    <phone_ext>2501</phone_ext>
    <email>kmanotham@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tanaporn Ratanasuwan, Dr</last_name>
    <phone>662 3539799</phone>
    <phone_ext>9722</phone_ext>
    <email>tratanas@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lerdsin General Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10500</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Krissanapong Manotham, Dr</last_name>
      <phone>662 3539799</phone>
      <phone_ext>2501</phone_ext>
      <email>kmanotham@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Tanaporn Ratanasuwan, Dr</last_name>
      <email>tratanas@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Krissanapong Manotham, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2009</study_first_submitted>
  <study_first_submitted_qc>July 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2009</study_first_posted>
  <last_update_submitted>July 29, 2009</last_update_submitted>
  <last_update_submitted_qc>July 29, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2009</last_update_posted>
  <responsible_party>
    <name_title>Division of Nephrology, Department of Medicine</name_title>
    <organization>Lerdsin General Hospital</organization>
  </responsible_party>
  <keyword>ACEI, ARB, DN, aliskiren, proteinuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

